Evolus, Inc. (NASDAQ:EOLS) CMO Sells $60,147.36 in Stock

Evolus, Inc. (NASDAQ:EOLS) CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the sale, the chief marketing officer now directly owns 95,671 shares of the company’s stock, valued at approximately $1,268,597.46. This represents a 4.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Evolus Stock Performance

Shares of EOLS traded down $0.22 during mid-day trading on Thursday, reaching $13.25. 663,321 shares of the company’s stock traded hands, compared to its average volume of 593,757. The business’s 50-day moving average price is $13.36 and its 200-day moving average price is $13.91. The stock has a market capitalization of $842.53 million, a P/E ratio of -14.56 and a beta of 1.28. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a 12 month low of $9.25 and a 12 month high of $17.82.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on EOLS shares. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a research note on Wednesday, March 5th. Finally, Barclays upped their target price on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in EOLS. KBC Group NV acquired a new position in Evolus in the fourth quarter worth approximately $49,000. IFP Advisors Inc boosted its stake in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after buying an additional 4,709 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus in the 4th quarter valued at $106,000. Rafferty Asset Management LLC acquired a new stake in shares of Evolus in the 4th quarter valued at $115,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Evolus in the 4th quarter valued at $118,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.